Conditional sentence

The Institute for Functional Medicine Rises to the White House Challenge to End Hunger and Build Healthy Communities

Retrieved on: 
Thursday, February 29, 2024

In support of this call and as an extension of the organization’s work around the globe, IFM focused its commitment on the integration of nutrition and health.

Key Points: 
  • In support of this call and as an extension of the organization’s work around the globe, IFM focused its commitment on the integration of nutrition and health.
  • During the Feb. 27th White House event, U.S. Representative Jim McGovern stressed the significance of food as medicine and the need for all healthcare practitioners to be trained in the importance of nutrition throughout their medical education – a claim IFM confidently supports.
  • “Understanding how nutrition supports health and well-being is critical to ending hunger and creating healthy communities,” states IFM Chief Executive Officer, Amy R. Mack, MSES/MPA.
  • “Nutrient rich foods fuel the body, reduce inflammation, and prevent or reduce chronic diseases, which promotes optimal function and longevity.

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 remained level with the fourth quarter of 2022 at $0.8 million.
  • As of December 31, 2023, Virios Therapeutics’ cash totaled $3.3 million.
  • The Company believes it has sufficient resources to fund operations into the fourth quarter of 2024.

ACADEMY OF NUTRITION AND DIETETICS CELEBRATES BEYOND THE TABLE FOR 2024 NATIONAL NUTRITION MONTH® IN MARCH

Retrieved on: 
Thursday, February 29, 2024

Chicago, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics kicks off its annual National Nutrition Month® campaign on March 1.

Key Points: 
  • Chicago, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics kicks off its annual National Nutrition Month® campaign on March 1.
  • National Nutrition Month® started in 1973 as National Nutrition Week, and it became a month-long observance in 1980 in response to growing interest in nutrition.
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.
  • The Academy is committed to improving health and advancing the profession of dietetics through research, education and advocacy.

LiveCare Inc.(OTCMKTS: LVCE) Enters Hypertension Market, Enhancing Healthcare Monitoring for U.S. Adults

Retrieved on: 
Wednesday, February 28, 2024

This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.

Key Points: 
  • This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.
  • A distinguishing feature of the LiveCare Health approach is the real-time transmission of device readings to the health center.
  • The demand for blood pressure monitoring devices is substantial and expanding, fueled by growing recognition of the critical role of early hypertension detection and management.
  • With an estimated 75 million American adults diagnosed with high blood pressure, the potential impact of LiveCare Inc.'s new device is considerable.

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Wednesday, February 28, 2024

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.

Key Points: 
  • ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.
  • On behalf of the Virios directors and the executive team, we would like to provide a corporate progress report on several key topics as we proceed through the first quarter of 2024.
  • Approval of this proposal does not commit the Company to the execution of a reverse stock split.
  • The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses.

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases

Retrieved on: 
Wednesday, February 28, 2024

Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.

Key Points: 
  • Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.
  • A substantially de-risked platform and two first-in-class gene therapies heading to the clinic, having the potential to become future blockbusters.
  • PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital.
  • PulseSight is currently raising a Series A financing round to advance its programs into clinical proof-of-concept.

WELL Health Founder & CEO Hamed Shahbazi Appointed Chairman of the Board of HEALWELL AI

Retrieved on: 
Tuesday, February 27, 2024

Hamed Shahbazi, Founder, Chairman and CEO of WELL Health Technologies has been appointed Chairman of HEALWELL AI, a global leader in AI powered preventative care.

Key Points: 
  • Hamed Shahbazi, Founder, Chairman and CEO of WELL Health Technologies has been appointed Chairman of HEALWELL AI, a global leader in AI powered preventative care.
  • Mr. Hamed Shahbazi is currently the Chairman and CEO of WELL, Canada's largest owner operator of outpatient medical clinics and leading digital health service providing software and services to more than one third of all Canadian physicians.
  • Mr. Shahbazi has served on the Board of HEALWELL since its launch on October 1, 2023.
  • Hamed Shahbazi, Founder and CEO of WELL commented on his appointment, “As a co-founder of HEALWELL, I am personally very proud and excited to take on the role of Chairman for HEALWELL AI given the enormous importance of the shared mission and objective we have between WELL and HEALWELL.

Empowering Women in Dentistry: Austin Oral Surgery’s 2024 Lucy Hobbs Project Seeks to Overcome Burnout, Cultivate Belonging and End Human Trafficking

Retrieved on: 
Tuesday, February 27, 2024

In fact, Deloitte’s Human Capital Trends report ranked belonging as the top human capital issue that organizations face today.

Key Points: 
  • In fact, Deloitte’s Human Capital Trends report ranked belonging as the top human capital issue that organizations face today.
  • End Human Trafficking, Ignite Hope will be presented by Liz Griffin, the executive director of Unbound Now Austin, a 501c3 nonprofit that is dedicated to extinguishing human trafficking and igniting hope.
  • Lucy Hobbs Project attendees will have the opportunity to earn up to five units of continuing education credit.
  • In addition, the event will include a brunch buffet, networking, shopping and opportunities to raise funds and awareness for Unbound Now Austin.

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Retrieved on: 
Friday, February 23, 2024

“These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.

Key Points: 
  • “These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.
  • These analyses present the overall attack rate progression and attack rate progression stratified by severity (i.e., number of attacks at baseline), prior prophylaxis and C1-INH level and function.
  • These findings further demonstrate that ORLADEYO can help maintain disease control in patients with lower baseline attack rates and further reduce attack rates in patients with more active disease.
  • Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday, February 23, 3:15-4:15 p.m.

Fobi AI Chosen To Participate in the 2024 Comcast NBCUniversal SportsTech Accelerator Program

Retrieved on: 
Thursday, February 22, 2024

VANCOUVER, BC, Feb. 22, 2024 (GLOBE NEWSWIRE) -- February 22, 2024, Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that Fobi has been selected among nine other companies from over 1,500 applicants across 52 countries for this year’s sports tech accelerator program.

Key Points: 
  • Fobi selected among nine other companies from over 1,500 applicants across 52 countries for this year's sports tech accelerator program.
  • VANCOUVER, BC, Feb. 22, 2024 (GLOBE NEWSWIRE) -- February 22, 2024, Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that Fobi has been selected among nine other companies from over 1,500 applicants across 52 countries for this year’s sports tech accelerator program.
  • Since the first class in 2021, SportsTech alumni have achieved 132 pilots, partnerships, and commercial deals with consortium partners
    PHILADELPHIA, February 22, 2024 —Today, 10 companies were accepted into the fourth class of the Comcast NBCUniversal SportsTech Accelerator , powered by Boomtown.
  • Fobi AI uses automation, AI, and real-time data intelligence to enhance global customer engagement, personalization, and activation.